https://www.yiliao.com/index.php?action=history&feed=atom&title=RRMM
RRMM - 版本历史
2026-04-18T12:38:46Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=RRMM&diff=314032&oldid=prev
223.160.138.80：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-12T03:30:39Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[复发或难治性多发性骨髓瘤]]</strong>（<strong>[[RRMM]]</strong>）是指在接受过初始治疗并获得缓解后，病情再次进展或对当前治疗无反应的 <strong>[[多发性骨髓瘤]]</strong>（<strong>[[MM]]</strong>）阶段。随着蛋白酶体抑制剂、免疫调节剂及 <strong>[[CD38]]</strong> 单抗的广泛应用，临床上出现了大量针对上述三类药物均耐药的 <strong>[[三重耐药]]</strong>（Triple-class refractory）患者。进入 2026 年，<strong>[[RRMM]]</strong> 的治疗格局发生了剧变，以 <strong>[[BCMA]]</strong> 为靶点的 <strong>[[CAR-T]]</strong> 细胞疗法（如 <strong>[[伊基奥仑赛]]</strong>、<strong>[[西达基奥仑赛]]</strong>）和 <strong>[[双特异性抗体]]</strong>（如 <strong>[[泰立奇]]</strong>、<strong>[[艾瑞珂]]</strong>）已成为后线挽救治疗的标准方案，显著延长了末线患者的生存期。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">复发或难治性多发性骨髓瘤</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">RRMM · Triple-class Refractory MM</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">RRMM: Advanced stage of Multiple Myeloma progression</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px;">核心靶标：<strong>[[BCMA]]</strong> / <strong>[[GPRC5D]]</strong></div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%; font-weight: normal;"><strong>[[ICD-10]]</strong></th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">C90.00</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; font-weight: normal;"><strong>[[ICD-11]]</strong></th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2A80.0</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; font-weight: normal;">常用标志物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">M蛋白、轻链、<strong>[[BCMA]]</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; font-weight: normal;">高危遗传学</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">del(17p)、t(4;14)、1q21+</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; font-weight: normal;">主要疗法</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;"><strong>[[CAR-T]]</strong>、<strong>[[双特异性抗体]]</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; font-weight: normal;">相关实体</th><br />
<td style="padding: 12px; color: #0f172a;"><strong>[[IMWG]]</strong> / <strong>[[NCCN]]</strong></td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">发病机制：克隆演变与免疫逃逸</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
<strong>[[RRMM]]</strong> 的发生是恶性浆细胞在治疗压力下不断进化的结果，其核心特征包括：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;">克隆异质性：随着病程进展，对化疗敏感的克隆被清除，具有 <strong>[[TP53]]</strong> 突变或高危细胞遗传学改变的耐药克隆逐渐占据主导地位。</li><br />
<li style="margin-bottom: 12px;">靶点丢失：在接受针对 <strong>[[BCMA]]</strong> 的 <strong>[[CAR-T]]</strong> 或双抗治疗后，部分肿瘤细胞会通过基因缺失或下调抗原表达实现免疫逃逸。</li><br />
<li style="margin-bottom: 12px;"><strong>[[髓外病变]]</strong>（EMD）：恶性细胞脱离骨髓微环境，在皮肤、肝脏或浆膜腔形成浸润，这是 <strong>[[RRMM]]</strong> 患者预后极差的标志。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">耐药层级与临床特征</h2><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%; font-weight: bold;">耐药分类</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569; font-weight: bold;">定义标准</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af; font-weight: bold;">临床干预方向</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">双重耐药</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">对一种 <strong>[[PI]]</strong>（如硼替佐米）和一种 <strong>[[IMiD]]</strong>（如来那度胺）均耐药。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">引入 <strong>[[CD38]]</strong> 单抗联合方案。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>[[三重耐药]]</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">对 <strong>[[PI]]</strong>、<strong>[[IMiD]]</strong> 及 <strong>[[CD38]]</strong> 单抗均产生耐药。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">优先考虑 <strong>[[BCMA]]</strong> 靶向免疫治疗。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">五重耐药</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">对两种 <strong>[[PI]]</strong>、两种 <strong>[[IMiD]]</strong> 及 <strong>[[CD38]]</strong> 单抗均耐药。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">尝试 <strong>[[GPRC5D]]</strong> 靶点或 <strong>[[XPO1]]</strong> 抑制剂。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗策略：后线挽救与靶点轮替</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
针对 <strong>[[RRMM]]</strong> 的现代诊疗强调“深度缓解”与“生存质量”的平衡：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;">自体 <strong>[[CAR-T]]</strong> 疗法：通过回输修饰后的 T 细胞，<strong>[[伊基奥仑赛]]</strong> 和 <strong>[[西达基奥仑赛]]</strong> 在末线患者中实现了极高的 <strong>[[MRD]]</strong> 转阴率。</li><br />
<li style="margin-bottom: 12px;">双特异性抗体（BsAb）：<strong>[[泰立奇]]</strong>（靶向 BCMA/CD3）和 <strong>[[泰立唯]]</strong>（靶向 GPRC5D/CD3）提供了现货型治疗选择，适用于无法等待 <strong>[[CAR-T]]</strong> 制备的急症进展患者。</li><br />
<li style="margin-bottom: 12px;">靶点轮替逻辑：当 <strong>[[BCMA]]</strong> 疗法进展后，临床推荐转向针对 <strong>[[GPRC5D]]</strong> 或 <strong>[[FcRH5]]</strong> 等新靶点的药物。</li><br />
<li style="margin-bottom: 12px;">支持治疗：包括针对 <strong>[[骨相关事件]]</strong> 的双膦酸盐治疗和针对免疫抑制的 <strong>[[IVIG]]</strong> 补充。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[三重耐药]]</strong>：当前 <strong>[[RRMM]]</strong> 定义的核心，决定了后续治疗强度的选择。</li><br />
<li style="margin-bottom: 8px;"><strong>[[MRD]]</strong>：微小残留病，其持续阴性是评估 <strong>[[RRMM]]</strong> 长期预后的金标准。</li><br />
<li style="margin-bottom: 8px;"><strong>[[BCMA]]</strong>：目前 <strong>[[RRMM]]</strong> 免疫治疗最重要的导航靶点。</li><br />
<li style="margin-bottom: 8px;"><strong>[[自交异体干细胞移植]]</strong>：对于部分多次复发患者，<strong>[[造血干细胞移植]]</strong> 仍是桥接治疗的一种考虑。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] Kumar SK, et al. (2024/2025). Managing relapsed or refractory multiple myeloma: current strategies and future directions. <strong>[[The Lancet Haematology]]</strong>.<br />
<br><span style="color: #475569;">[权威点评]：该综述强调了 <strong>[[CAR-T]]</strong> 疗法前置至早期复发阶段对于改善长期生存的决定性意义。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>[[IMWG]]</strong> Consensus Criteria (2025 Update). Definition and response assessment in <strong>[[RRMM]]</strong> patients in the era of bispecifics. <strong>[[Blood]]</strong>.[Academic Review]<br />
<br><span style="color: #475569;">[学术点评]：更新了针对新型免疫疗法的疗效评估标准，特别增加了针对抗原丢失现象的监测指引。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
复发或难治性多发性骨髓瘤 (RRMM) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[BCMA]]</strong>•<strong>[[CD38]]</strong>•<strong>[[GPRC5D]]</strong>•<strong>[[FcRH5]]</strong>•<strong>[[SLAMF7]]</strong></td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心药物</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[伊基奥仑赛]]</strong>•<strong>[[西达基奥仑赛]]</strong>•<strong>[[泰立奇]]</strong>•<strong>[[泰立唯]]</strong>•<strong>[[泊马度胺]]</strong></td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">并发症管理</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[CRS]]</strong>•<strong>[[ICANS]]</strong>•<strong>[[低丙种球蛋白血症]]</strong>•<strong>[[高钙血症]]</strong></td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究趋势</td><br />
<td style="padding: 10px 15px; color: #334155;"><strong>[[双靶点CAR-T]]</strong>•<strong>[[异体通用型CAR-T]]</strong>•<strong>[[免疫检查点抑制剂联合方案]]</strong>•<strong>[[CELMoDs]]</strong></td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.138.80